Vivos Therapeutics Inc expected to post a loss of 28  cents a share - Earnings Preview

Vivos Therapeutics

09/08/2022 03:04

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 10
(estimated). 
    * The Highlands Ranch Colorado-based  company is expected to
report  a 15.3% decrease in revenue to $3.809 million from $4.5
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vivos Therapeutics
Inc is
for a loss of 28 cents per share. For the same quarter last
year, the company reported a loss of 19 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $4.5​, above​ its last closing price
of $1.30. ​​​

This summary was machine generated August 9 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated